Search Results

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies Brief Summary: The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.…

CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Brief Summary: The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and…

Jennifer Vaz, MD received her medical degree from the Medical College of Virginia before completing a residency in gynecology and obstetrics at Inova Fairfax Hospital. She completed a gynecologic oncology fellowship at the Medical College of Georgia. Following her medical training, Dr. Vaz served as both a gynecologic oncologist and assistant professor of obstetrics and…

A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment – DS1062-328 MOA: Dato-DXD is an ADC that comprises a recombinant humanized anti-TROP2 IgG1…

Mark G. Goldstein, MD, FACP is Board Certified in medical oncology and hematology.  Dr. Goldstein earned a B.S. in genetics at the University of Georgia, then his medical degree from St. George’s University.  He completed his residency at the University of Connecticut with two Commendations for Excellence in Patient Care, followed by a fellowship in…

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (V940-009) MOA: V940 is a lipid encapsulated mRNA based Individualized Neoantigen Therapy (INT) encoding neoantigens to induce specific T cells…